Open Trials
At Shenandoah Oncology, research is an integral part of our comprehensive efforts to provide cancer patients in our community with access to the latest and most advanced therapies and treatment options. As a member of US Oncology Research and as a clinical research affiliate of VCU Massey Cancer Center, we are pleased to share this list of clinical trials currently enrolling at our practice.
BREAST CANCER – ADJUVANT
NSABP B-53 / S1207
Phase 3 study comparing standard adjuvant endocrine therapy to the combination of standard endocrine therapy plus everolimus in patients with high-risk hormone receptor positive and HER2 negative breast cancer. Studies show that the addition of everolimus to standard endocrine therapy can delay disease progression in metastatic disease, and the goal of this study is to establish if the combination of everolimus and standard endocrine therapy will increase the cure rate in the adjuvant setting.
NRG-BR003
Phase 3 study of adjuvant therapy comparing doxorubicin and cyclophosphamide followed by weekly paclitaxel with or without carboplatin for node-positive or high-risk node-negative triple negative invasive breast cancer.
NRG-BROO6
Phase 3 randomized study of Pembrolizumab versus observation in patient with triple negative breast cancer who have ≥1cm residual disease or positive lymph nodes after neoadjuvant chemotherapy
BREAST CANCER – RECURRENT/ADVANCED
A171601
Phase 2 study assessing the tolerability of Palbociclib with Letrozole or Fulvestrant in patients aged 70 or older with hormone receptor positive and HER-2 negative metastatic breast cancer. Open label, single-arm study.
CHRONIC LYMPHOCYTIC LYMPHOMA
USOR 15-005
InformCLL: A disease registry for patients with chronic lymphocytic leukemia. The study will track current treatment patterns among CLL patients and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
LUNG CANCER, NON SMALL CELL
NONE AT THIS TIME
LYMPHOMA
NONE AT THIS TIME
MULTIPLE MYELOMA
NONE AT PRESENT
OVARIAN
NONE AT PRESENT
PROSTATE
NONE AT PRESENT
RENAL CELL
NONE AT PRESENT
THERAPEUTIC
USOR 18-109
A prospective observational study to estimate the incidence of febrile neutropenia (FN) among subjects with non-myeloid malignancies at high risk for FN and receiving Neulasta onpro kit or other physicians choice for prophylaxis of FN.
WEIGHT LOSS
BWEL
Randomized phase 3 study evaluating the role of weight loss in adjuvant treatment of overweight or obese women with early HER-2 negative breast cancer.